Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: Results of cancer and leukemia group B 159904

Journal of Thoracic Oncology

Volumn 3, Issue 4, 2008, Pages 417-421

  Kratzke, Robert A ^a   Wang, Xiaofei ^b   Wong, Long ^a   Kratzke, Marian G ^a   Green, Mark R ^c   Vokes, Everett E ^d   Vogelzang, Nicholas J ^e   Kindler, Hedy L ^d   Kern, Jeffrey A ^f  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Roper St Francis Healthcare   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e NEVADA CANCER INSTITUTE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Mesothelioma; Methylation; p16INK4a

Indexed keywords

5,6 DIHYDROAZACITIDINE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GENE PRODUCT;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; EXON; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MESOTHELIOMA; MONOTHERAPY; P16 INK4A GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 41749102001     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318168da0a     Document Type: Article

References (19)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
2. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998;113(1 Suppl):66S-73S.
3. Sherr CJ. Cancer Cell Cycles. Science 1996;274:1672-1677.
4. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002;23:1127-1130.
5. Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J, et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995;87:1870-1875.
6. Frizelle SP, Grim J, Zhou J, Gupta P, Curiel DT, Geradts J, et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998;16:3087-3095.
7. Frizelle SP, Rubins JB, Zhou JX, Curiel DT, Kratzke RA. Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther 2000;7:1421-1425.
8. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-699.
9. Wong L, Zhou J, Anderson D, Kratzke RA. Inactivation of p16(INK4a) expression in malignant mesothelioma by methylation. Lung Cancer 2002;38:131-136.
10. Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene 1995;11:1211-1216.
11. Samuels BL, Herndon Jn, Harmon DC, Carey R, Aisner J, Corson JM, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer 1998;82:1578-1584.
12. Vogelzang NJ, Herndon Jn, Cirrincione C, Harmon DC, Antman KH, Corson JM, et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 1997;79:2237-2242.
13. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9865.
14. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005;2(Suppl 1):S4-11.
15. Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007;138:3-11.
16. Lavelle DE. The molecular mechanism of fetal hemoglobin reactivation. Semin Hematol 2004;41(4 Suppl 6):3-10.
17. Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006;7:257-261.
18. Destro A, Ceresoli GL, Baryshnikova E, Garassino I, Zucali PA, De Vincenzo F, et al. Gene methylation in pleural mesothelioma: Correlations with clinico-pathological features and patient's follow-up. Lung Cancer 2007 [Epub ahead of print].
19. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, et al. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006;54:109-116.